This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Post-Approval Study of the Implantable Miniature Telescope (PAS-01)

This study is enrolling participants by invitation only.
Information provided by (Responsible Party):
VisionCare, Inc. Identifier:
First received: November 13, 2012
Last updated: October 27, 2016
Last verified: October 2016

The objective of the PAS-01 study is to assess the safety of the intraocular as measured by the cumulative incidence of patients who within 5 years after implantation experience persistent vision-impairing corneal edema (corneal edema leading to persistent loss of best corrected distance visual acuity >2 lines from pre-surgery baseline level).

The study will test the null hypothesis that the percentage of patients who experience persistent vision-impairing corneal edema is >17% against the alternative that the percentage is <17%. The null hypothesis will be rejected if the upper bound of the two-sided 95% confidence integral for the observed percentage is <17%.

Condition Intervention
AMD Device: Implantable Miniature Telescope

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Post-approval Study of VisionCare's Implantable Miniature Telescope (by Dr. Isaac Lipshitz) in Patients With Bilateral Severe to Profound Central Vision Impairment Assoc. With End-stage Age-related Macular Degeneration

Resource links provided by NLM:

Further study details as provided by VisionCare, Inc.:

Primary Outcome Measures:
  • Long term safety study of implantable miniature telescope [ Time Frame: 5 years after implantation ]
    Number of persistent vision impairing corneal edema adverse events

Estimated Enrollment: 770
Study Start Date: August 2010
Estimated Study Completion Date: December 2028
Estimated Primary Completion Date: December 2023 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Implantable Miniature Telescope
Post approval study
Device: Implantable Miniature Telescope
Device - Implantable Miniature Telescope

Detailed Description:
ECD sub-study. At investigative sites participating in the ECD Sub-Group study, corneal endothelial cell density will be measured by non-contact specular microscopy in a subgroup of 150 patients enrolled in the IMT-PAS-01 in the eye schedule for and implanted with the intraocular telescope at study entry, 3 months, 12, months, 24 months, 36 months, 48 months and 60 months.

Ages Eligible for Study:   65 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • stable severe (BVDCA of 10/160 or poorer) to profound (BCDVA of 20/800 or better) vision impairment caused by bilateral central scotomas associated with end-stage age-related macular degeneration.
  • 65 years of age or older
  • retinal findings of geographic atrophy or disciform scar with foveal involvement
  • visually significant cataract
  • agree to undergo pre- and post-surgery training and assessment
  • achieve at least a 5-letter improvement with external telescope
  • have adequate peripheral vision in the eye not scheduled for surgery

Exclusion Criteria:

  • Stargardt's macular dystrophy
  • Anterior chamber depth < 3.0mm
  • Presence of corneal guttate
  • Do not meet minimum age and endothelial cell density requirements
  • evidence of CNV or treatment of CNV within the past 6 months
  • cognitive impairment that would interfere with ability to understand and complete Acceptance of Risk and Informed Decision Agreement or prevent proper training/rehabilitation
  • previous intraocular or cornea surgery of any kind in operative eye, including any type of surgery for either refractive or therapeutic purposes or who have prior or expected ophthalmic related surgery within 30 days preceding intraocular telescope surgery
  • history of steroid-responsive rise in intraocular pressure, uncontrolled glaucoma, or preoperative IOP >22 mm Hg while on maximum medication
  • known sensitivity to post-operative medications
  • history of eye rubbing or an ocular condition that predisposes eye rubbing
  • myopia >6.0 D
  • hyperopia >4.0D
  • axial length <21mm
  • narrow angle, i.e., <Schaffer grade 2
  • cornea stromal or endothelian dystrophies, including guttate
  • inflammatory ocular disease
  • zonular weakness/instability of crystalline lens, or pseudoexfoliation
  • diabetic retinopathy
  • untreated retinal tears
  • retinal vascular disease
  • optic nerve disease
  • history of retinal detachment
  • intraocular tumor
  • retinitis pigmentosa
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01757132

  Show 26 Study Locations
Sponsors and Collaborators
VisionCare, Inc.
Principal Investigator: Oliver D Schein, MD Johns Hopkins University
  More Information

Responsible Party: VisionCare, Inc. Identifier: NCT01757132     History of Changes
Other Study ID Numbers: PAS-01
Study First Received: November 13, 2012
Last Updated: October 27, 2016 processed this record on August 18, 2017